This model is also of direct clinical relevance because the pathogenesis of VCP/p97-related bone disease is incompletely understood; and whilst proteasome inhibitors purportedly stimulate bone regeneration in myeloma patients, the effects of drugs targeting VCP/p97 on bone have not been established [[38], [39], [40]]. Here, VCP is linked to plasma cell myeloma.